Opzelura (Ruxolitinib Cream)

Ruxolitinib cream is a medicine used to treat eczema (atopic dermatitis) and vitiligo, a condition that causes patches of skin to lose color. It is a cream you rub on the skin. It works by calming signals in the skin's immune system that cause itching, inflammation and color loss.

Brand names:Opzelura
Medication

What people taking Opzelura (Ruxolitinib Cream) report

Every report comes from a Lived member, sent anonymously.

Have you tried Opzelura (Ruxolitinib Cream) for Vitiligo?

NameHow it went

About Opzelura (Ruxolitinib Cream)

What It's For

Opzelura is the brand name for ruxolitinib cream, a prescription medicine applied to the skin. It is approved for two skin conditions. The first is mild to moderate atopic dermatitis, the most common form of eczema, in people 2 years and older whose immune systems are not weakened and whose eczema has not been controlled well enough by other prescription creams or ointments, or who should not use them. The second is nonsegmental vitiligo, a condition in which the cells that give skin its color are destroyed, leaving pale or white patches, in people 12 and older. Ruxolitinib belongs to a group of medicines called Janus kinase (JAK) inhibitors. Dermatology guidelines list topical JAK inhibitors among the recommended prescription options for eczema in adults, alongside steroid creams and other nonsteroid treatments. The same ingredient is also sold as Jakafi tablets for certain blood and bone marrow disorders. Those tablets have different uses and doses and are not interchangeable with the cream.

How It Works

Many immune signals in the skin are carried by messenger proteins called cytokines. To take effect, these signals pass through enzymes inside cells called Janus kinases, or JAKs. Ruxolitinib blocks two of them, JAK1 and JAK2, which turns that signaling down. In eczema, this calms the inflammation behind the redness, rash and itch. In vitiligo, immune cells attack the skin's pigment-producing cells, so quieting that immune activity in the treated skin can allow color to return gradually in some people. Researchers have not pinned down exactly which part of this effect produces the benefit. Although the cream is applied to the skin, some of the medicine reaches the bloodstream. In studies it was measurable in the blood of everyone who used it. That is why the cream shares warnings with JAK inhibitor tablets, and why the label caps how much can be used.

Dosage & Administration

Opzelura comes as a 1.5% cream in 60 gram and 100 gram tubes. A thin layer is applied twice a day to the affected skin only. It is for use on the skin alone, so keep it out of the eyes, mouth and vagina, and wash your hands after applying it unless your hands are being treated. Do not cover treated skin with an airtight (occlusive) dressing such as plastic wrap. Because some of the medicine is absorbed, the label limits both the area treated and the amount used. For eczema, it is applied to no more than 20% of the body's skin; for vitiligo, no more than 10%. People 12 and older should use no more than one 60 gram tube a week or one 100 gram tube every two weeks. Children 2 to 11 using it for eczema should use no more than one 60 gram tube every two weeks. If a dose is missed, apply it when you remember unless the next one is nearly due, and do not apply extra to make up for it.

Side Effects

In the eczema trials, the side effects seen more often than with a plain cream were mostly minor: colds and other nose and throat infections, along with occasional diarrhea, hives, ear infections and inflamed hair follicles. Children aged 2 to 11 were somewhat more likely to have irritation or pain where the cream was applied, fever, or a drop in white blood cells on blood tests. In the vitiligo trials, acne-like bumps, itching or redness at the treated spots and headache were the most common. Because the medicine can lower the body's defenses, contact the prescriber right away about signs of infection: fever, chills, a cough or shortness of breath, skin that is warm, red and painful, or burning when you urinate. Shingles, a painful rash caused by the chickenpox virus reawakening, has occurred and may mean pausing the cream until it clears. Unusual bleeding or bruising can signal low blood counts and is a reason to stop the cream and call the prescriber right away.

Interactions & Warnings

Opzelura carries an FDA boxed warning, the agency's most serious type of warning, shared with other JAK inhibitors. It covers serious infections, a higher death rate, cancers including lymphoma, heart attack and stroke, and blood clots in the legs or lungs. Much of this comes from a large study of a JAK inhibitor tablet in people 50 and older with rheumatoid arthritis and at least one heart risk factor. How much of that risk applies to a cream used on limited skin is not known, and blood clots and cancers were reported in the cream's own trials. The label advises avoiding the cream in people at increased risk of blood clots, and current or past smokers and people with a history of cancer or heart disease should weigh the benefits and risks with their prescriber. Signs of a blood clot, heart attack or stroke mean stopping the cream and getting emergency care (call 911): chest pain or pressure, sudden shortness of breath, sudden weakness or numbness of an arm or leg, trouble speaking, a sudden severe headache, or a painful, swollen, warm or red leg. Skin cancers (basal cell and squamous cell carcinoma) have occurred in people using the cream, so periodic skin checks, protective clothing and broad-spectrum sunscreen are advised. Before starting, tell the prescriber about hepatitis B or C, past exposure to tuberculosis, or frequent infections; the cream is not started during an active serious infection. Opzelura is not recommended together with other JAK inhibitors, strong immune-suppressing drugs such as azathioprine or cyclosporine, or biologics (injected antibody treatments such as dupilumab, sold as Dupixent for eczema). Medicines that strongly block the liver enzyme CYP3A4, such as the antifungal pill ketoconazole, can raise ruxolitinib levels and should be avoided. Pregnancy data are too limited to judge the risk. The label advises not breastfeeding during treatment and for about four weeks after the last dose.

What to Expect

For eczema, the cream is used on and off rather than nonstop: it is applied during a flare, stopped once the itch, rash and redness clear, and can be used again if the eczema returns. In the main trials, about half of people 12 and older had clear or almost clear skin after eight weeks, compared with roughly 8 to 15% using a plain cream, and about half had a substantial drop in itch. Results in children 2 to 11 were similar. If the eczema has not improved within eight weeks, it is time to be re-examined. Vitiligo works on a much slower clock. In the trials, about 3 in 10 people regained at least three-quarters of the color in facial patches after 24 weeks, compared with about 1 in 10 using a plain cream, and more people responded as treatment continued through a year. A good response may take longer than 24 weeks, but if the improvement is not meaningful by then, the prescriber should reassess the plan. Follow-up includes periodic skin checks. Blood counts are checked when the prescriber thinks it is needed, for example in someone with a history of low counts.

Questions to Ask Your Doctor

  1. 1.Why is Opzelura a better fit for me than a steroid cream or another nonsteroid option?
  2. 2.Given my age, smoking history and heart or clot risk, how do the boxed warning risks apply to me?
  3. 3.How much of my skin can I treat, and how long should one tube last?
  4. 4.When should we judge whether it is working, and what would we try next if it is not?
  5. 5.Do any of my other medicines, or plans for pregnancy or breastfeeding, affect whether I can use it?

Last reviewed • Oct 2026

Educational content, not medical advice.